TABLE 3.

Preferences for daily oral versus weekly injectable medications before and after product‐specific information was provided to patients

		Product‐specific preference c
		Product X (weekly injectable dulaglutide), n (%)	Product Y (daily oral semaglutide), n (%)	Total, N (%)
	Weekly injectable	132 (22.0)	9 (1.5) a	141 (23.5)
Initial preference b	Daily oral	153 (25.5) a	306 (51.0)	459 (76.5)
	Total	285 (47.5)	315 (52.5)

^a Switchers.

^b P < 0.0001 for general preference for weekly injectable (95% confidence interval [CI] 20.1–26.9) vs. daily oral (95% CI 73.1–79.9) comparison.

^c P = 0.2207 for preference for Product X (95% CI 43.5–51.5) vs. Product Y (95% CI 48.5–56.5) comparison.